The Oncology Institute, Inc. (NASDAQ:TOI) CEO Daniel Virnich Purchases 22,640 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) CEO Daniel Virnich acquired 22,640 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of $1.04 per share, for a total transaction of $23,545.60. Following the completion of the transaction, the chief executive officer now owns 724,363 shares in the company, valued at approximately $753,337.52. The trade was a 3.23 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Oncology Institute Stock Performance

Shares of TOI stock opened at $1.14 on Friday. The company has a market cap of $86.14 million, a P/E ratio of -1.46 and a beta of 0.41. The firm has a fifty day moving average price of $0.86 and a 200 day moving average price of $0.48. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The Oncology Institute, Inc. has a 12 month low of $0.13 and a 12 month high of $1.63.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The business had revenue of $100.27 million for the quarter, compared to analyst estimates of $109.15 million.

Hedge Funds Weigh In On Oncology Institute

Several hedge funds have recently added to or reduced their stakes in TOI. HighTower Advisors LLC lifted its position in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after buying an additional 53,382 shares during the last quarter. FreeGulliver LLC raised its stake in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after acquiring an additional 412,578 shares in the last quarter. Tiff Advisory Services LLC raised its stake in Oncology Institute by 13.2% during the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock worth $921,000 after acquiring an additional 346,256 shares in the last quarter. Jane Street Group LLC lifted its position in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after acquiring an additional 109,769 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after acquiring an additional 12,000 shares in the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.